JENKEM(SH:688356)2024-04-29 09:54Financial Performance - The proposed cash dividend for 2023 is CNY 5.74 per 10 shares, totaling CNY 34,732,215.364, which represents 30.01% of the net profit attributable to shareholders [5]. - In 2023, the company's operating revenue decreased by 28.26% to CNY 292,118,400.90 compared to CNY 407,204,018.62 in 2022 [19]. - The net profit attributable to shareholders decreased by 38.05% to CNY 115,744,579.80, down from CNY 186,832,948.27 in the previous year [19]. - The basic earnings per share fell by 38.26% to CNY 1.92, compared to CNY 3.11 in 2022 [21]. - The company's cash flow from operating activities decreased by 35.54% to CNY 119,805,336.33, down from CNY 185,855,866.72 in the previous year [20]. - The company's total revenue for the reporting period was CNY 292.12 million, a decrease of 28.26% compared to the previous year [79]. - The net profit attributable to the parent company was CNY 115.74 million, down 38.05% year-on-year [79]. - Product sales revenue reached CNY 273.68 million, a decline of 15.68% year-on-year, with domestic sales at CNY 134.70 million (down 2.79%) and international sales at CNY 138.98 million (down 25.29%) [80]. - The gross profit margin for the company was 81.25%, a decrease of 3.6 percentage points year-on-year [81]. - The company experienced a significant drop in technical service revenue, which was CNY 1.76 million, down 78.47% year-on-year [80]. Research and Development - Research and development expenses accounted for 19.79% of operating revenue, an increase of 0.77 percentage points from the previous year [21]. - The company's R&D investment for 2023 totaled 57.82 million yuan, a decrease of 25.36%, representing 19.79% of sales revenue [33]. - The company has submitted 37 new patent applications in 2023 and received 16 new authorizations [33]. - The company completed the optimization and improvement of 16 derivative products and developed 106 new structural derivatives during the reporting period [126]. - The company is actively engaged in the development of second and third-generation PEG derivatives, focusing on specificity and functionality in drug modification [49]. - The company is innovating in the application of PEG materials for drug modification, with ongoing R&D for PEG-modified drugs and medical devices in various therapeutic areas [52]. Market and Business Strategy - The company is committed to maintaining a high level of R&D expenditure to enhance its competitive edge amid challenging market conditions [33]. - The company is focusing on enhancing production management and quality systems to adapt to new product demands and market conditions [82]. - The company aims to continue enhancing its R&D capabilities and improve the industrialization of R&D products while maintaining a focus on market-potential products and technologies [65]. - The company plans to explore new market opportunities and expand its product series to drive future growth [162]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals [180]. Governance and Compliance - The company has established a comprehensive governance structure, including a shareholders' meeting, board of directors, and supervisory board, ensuring clear responsibilities and coordination [168]. - The company is committed to transparent information disclosure, maintaining the interests of minority investors [170]. - The board of directors held 5 meetings in 2023, ensuring compliance with legal and regulatory requirements in decision-making processes [169]. - The audit committee held four meetings during the reporting period, ensuring oversight of financial reporting and compliance [193]. - The company has implemented a system to manage insider information, limiting the number of individuals with access to sensitive information [170]. Employee and Talent Management - The company has a total of 298 employees, with 46 in the parent company and 252 in major subsidiaries [199]. - Among the employees, there are 125 technical personnel, 77 production personnel, and 22 sales personnel, reflecting a diverse professional composition [199]. - The company aims to enhance employee motivation and efficiency through continuous optimization of personnel structure and compensation incentive systems [200]. - The compensation policy includes competitive salaries, bonuses, allowances, and various insurance benefits to attract local talent [200]. - The average salary of R&D personnel increased to CNY 28.62 million from CNY 20.03 million in the previous year [64]. Financial Position and Investments - The company reported a total of 404.85 million yuan in trading financial assets at the end of the period, an increase of 162.75 million yuan from the beginning of the year [28]. - The company has seen a continuous increase in early-stage customer project pipeline reserves, laying a solid foundation for future growth [32]. - The company reported a net cash outflow from investment activities, totaling -271.42 million RMB, compared to -79.45 million RMB in the previous year, mainly due to increased purchases of financial products [87]. - The company has invested 50 million in R&D for new technologies, focusing on sustainable solutions [180]. - The company aims to enhance capital efficiency and achieve certain financial returns through strategic investments in the healthcare sector [144].